Recombinant human interleukin-10 inhibits proliferation of vascular smooth muscle cells stimulated by advanced glycation end products and neointima hyperplasia after carotid injury in the rat

( views:80, downloads:0 )
Author:
OUYANG Ping()
PENG Li-sheng()
YANG Hong()
PENG Wen-lie()
WU Wen-Yan()
XU An-long()
Journal Title:
ACTA PHYSIOLOGICA SINICA
Issue:
Volume 55, Issue 02, 2003
DOI:
Key Word:
pathology;interleukin-10;muscle;smooth;vascular;advanced glycation end products;neointima hyperplasia

Abstract: The purposes of this study was to determine the effects of recombinant human interleukin-10 (rhIL-10) on proliferation of vascular smooth muscle cells (VSMCs) stimulated by advanced glycation end products (AGE) and neointima hyperplasia after rat carotid arterial injury. Rat aortic VSMCs were cultured and treated with rhIL-10 or AGE respectively, and then co-treated with rhIL-10 and AGE. Proliferation of VSMCs was quantified by colormetric assay. Cell cycle analysis was performed by flow cytomertry. Sprague-Dawley rats were treated with recombinant human IL-10 (rhIL-10) for 3 d after carotid arteries injury. The ratio of neointima to media area at the site of arterial injury was measured 28 d after balloon injury. The p44/42 MAPK activity was evaluated by the immunoblotting technique using anti-p44/42 phospho-MAPK antibody. Compared to control, AGE stimulated VSMCs proliferation. rhIL-10 alone had no effect on VSMCs growth. With AGE stimulation, rhIL-10, at dose as low as 10 ng/ml, inhibited VSMCs growth (P<0.05). The cell number in G0/G1 phase of AGE and rhIL-10 co-treatment group was higher than that of AGE treatment alone (P<0.01) by flow cytometry analysis. Compared with the control group of neointima hyperplasia in rats, the ratio of neointima to media area of recombinant human IL-10 group was reduced by 45% (P<0.01). The p44/42 MAPK activity was significantly enhanced by AGE. The AGE effects were opposed by rhIL-10. The anti-inflammatory cytokine rhIL-10 inhibits AGE-induced VSMCs proliferation. Recombinant human IL-10 also inhibited neointima hyperplasia after carotid artery injury in rats. The results suggest the possibility that recombinant human IL-10, as a potential therapeutic approach, prevents neointimal hyperplasia.

  • [1]Lusis AJ. Atherosclerosis. Nature 2000; 407:233-241.
  • [2]Jonasson L, Holm J, Skalli O, Gabbiani G, Hansson GK. Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J Clin Invest 1985;76:125-131.
  • [3]Clowes AW, Reidy MA, Clowes MM. Mechanisms of stenosis after arterial injury. Lab Invest 1983;49:208-215.
  • [4]Fab A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS, Virmani R. Pathology of acute and chronic coronary stenting in humans. Circulation 1999;99:44-52.
  • [5]Tanaka H, Sukhova GK, Swanson SJ,Clinton SK, Ganz P, Cybulsky MI, Libby P. Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury. Circulaion 1993;88:1788-1803.
  • [6]Rogers C, Weit FG, Karmovsky MJ, Edelman ER. Monocyte recruitment and neointimal hyperplasia in rabbits: coupled inhibitory effects of heparin. Arterioscler Thromb Vasc Biol 1996;16:1312-1318.
  • [7]Rogers C, Edelman ER, Simon DI. A mAb to the beta 2-leukocyte integrin Mac-1(CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci USA 1998;95:10134-10139.
  • [8]Kasper M, Funk RHW. Age-related changes in cells and tissues due to advanced glycation end products. Arch Geronot Geriatr 2001;32: 233-243.
  • [9]Moore KW, Malefyt RW, Coffman RL, Garra A. Interleukin-10 and the interleukin-10 receptor. Annu.Rev. Immunol 2001;19:683-765.
  • [10]Pober JS. Immunobiology of human vascular endothelium. Immunol Res 1999;19(2-3):225-232.
  • [11]King GL, Brownlee M.The cellular and molecular mechanisms of diabetic complications. Endocrinol Metab Clin North Am 1996;25(2):255-270.
  • [12]Kume S, Takeya M, Mori T, Sano H. Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta using a novel specific monoclonal antibody. Am J Pathol 1995; 147: 654-667.
  • [13]Sano H, Nagai R, Matsumoto K, Horiuchi S. Receptors for proteins modified by advanced glycation end products (AGE)-their functional role in atherosclerosis. Mech Aging Dev 1999; 107: 333-346.
  • [14]Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999;19:84(5):489-497.
  • [15]Huang JS, Guh JY, Chen HC, Hung WC, Lai YH, Chuang LY. Role of receptor for advanced glycation end products (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J Cell Biochem 2001;81:102-113.
  • [16]Satoh H,Togo M, Hara M, Miyata T, Han K, Maekawa H, Ohno M, Hashimoto Y, Kurokawa K, Watanabe T. Advanced glycation end products stimulate mitogen-activated protein kinase and proliferation in rabbit vascular smooth muscle cells. Biochem Biophys Res Commun 1997;239:111-115.
  • [17]Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochem Biophys Acta 2000;1498:99-111.
  • [18]Mallat Z, Heymes C, Ohan J, Faggin E, Leseche G, Tedgui A. Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death. Arterioscler Thromb Vasc Biol 1999;19:611-616.
  • [19]Uyemura K, Demer LL, castle SC, Jullien D, Berliner JA, Gately MK, Warrier RR, Pham N, Fogelman AM, Modlin RL. Cross-regulatory roles of interleukin-12 and IL-10 in atherosclerosis. J Clin Invest 1996;97:2130-2138.
  • [20]Krakauer T. IL-10 inhibits the adhesion of leukocytic cells to IL-1-activated human endothelial cells. Immunol Lett 1995;45:61-65.
  • [21]Suttles J, Milhorn DM, Miller RW, Poe JC, Wahlo LM, Stout RD. CD40 signaling of monocyte inflammatory cytokine synthesis through an ERK1/2-dependent pathway. J Biol Chem 1999;26: 5835-5842.
  • [22]Niiro H, Otsuka T, Ogami E, Yamaoka K, Nagano S, Akhoshi M, Nakashima H, Arinobu Y, Izuhara K, Niho Y. MAP kinase pathways as a route for regulatory mechanisms of IL-10 and IL-4 which inhibit COX-2 expression in human monocyte. Biochem Biophys. Res Commun 1998;250:200-205.
  • [23]Sato K, Nagayama H, Tadodoro K, Juji T, Takahashi TA. Extracellular signal-regulated kinase, stress-actived protein kinase/c-jun N-terminal kinase and p38 MAPK are involved in IL-10-mediated selective repression of TNF-α-induced activation and maturation of human peripheral blood monocyte-derived dendritic cells. J Immunol 1999;162:3865-3872.
  • [24]Kearney M, Pieczek A, Haley L, Losordo DW, Andres V, Schainfeld R, Roseenfield K, Isner JM. Histology of in-stent restenosis in patients with peripheral artery disease. Circulation 1997;95:1998-2002.
  • [25]Seitz M, Lotscher P, Dewald B, Towbing H, Gallati H, Baggiolini M. Interleukin-10 differentially regulates cytokine inhibitor and chemokine release from blood mononuclear cells and fibroblasts. Eur J Immunol 1995;25:1129-1132.
  • [26]Ranami M, Ollivier V, Khechai F, Vu T, Temisien C, Bridey F, de Prost D. Interleukin-10 inhibits endotoxin-induced tissue factor mRNA production by human monocytes. FEBS Lett 1993;334:114-116.
  • [27]Oehler L, Kollars M, Bohle B, Berer A, Reiter E, Lechner K, Geissler K. Interleukin-10 inhibits burst-forming unit-erythroid growth by suppression of endogenous granulocyte-macrophage colony-stimulating factor production from T cells. Exp Hematol 1999;27:217-223.
  • [28]Cunha FQ, Moncada S, Liew FY, Interleukin-10 inhibits the induction of nitric oxide synthase by interferon-gamma in murine macrophage. Biochem Biophys Res Commun 1992;182:1155-1159.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn